Company news: Pfizer, IMS Health and Elsevier

Share this article:
A Phase II trial showed that Pfizer's tofacitinib looks like it could be a contender for the ulcerative colitis market. The study surveyed 194 adults who received between 0.5 mg and 15 mg of the drug or a placebo over the course of eight weeks and found a clinical response at the eight-week mark. The findings were published Thursday in the New England Journal of Medicine. The pill is currently awaiting FDA approval for treating rheumatoid arthritis.

IMS Health acquired TTC, a Philadelphia-based clinical trial benchmarking and analytics firm. Terms were not disclosed. TTC's tools aim to enhance the speed, efficiency and cost-effectiveness of pharma's clinical trial planning and management activities. Clients include 17 of the top 20 pharmaceutical companies and eight of the ten largest contract research organizations, according to a statement.

Elsevier launched a new journal, Performance Enhancement & Health. The international, peer-reviewed journal critically explores the health implications of performance enhancement, “from steroid doping in elite athletes, right through to amphetamine use amongst truck drivers,” according to a statement from the publisher. The quarterly title will appeal to healthcare workers, as well as social scientists and those working in physical or sporting fields, Elsevier said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.